FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2032031944> ?p ?o ?g. }

• W2032031944 endingPage "395" @default.
• W2032031944 startingPage "384" @default.
• W2032031944 abstract "Background and Objectives Dihydropyrimidine dehydrogenase (DPD) plays a key role in the catabolism of 5-fluorouracil (5-FU) to 5-fluoro-5,6-dihydrouracil (5-FDHU), and as such, an impairment of DPD has been recognized as an important factor for altered 5-FU and 5-FDHU pharmacokinetics, predisposing patients to the development of severe 5-FU-associated toxicity. Our objectives were to avoid severe 5-FU toxicities in patients with greatly impaired 5-FU and 5-FDHU pharmacokinetics after the administration of a reduced test dose of 5-FU and to investigate possible 5-FU or 5-FDHU pharmacokinetic parameters of the test dose related to the most common drug toxicities that affect patients after the first cycle of 5-FU chemotherapy. Methods Pharmacokinetics of 5-FU/5-FDHU and DPD activity in peripheral blood mononuclear cells (PBMCs) were examined in 188 gastrointestinal cancer patients given a test dose of 5-FU, 250 mg/m2, 2 weeks before starting the planned 5-FU treatment of 370 mg/m2 plus L-folinic acid, 100 mg/m2, for 5 days every 4 weeks. Drug levels were examined by HPLC, and toxicities were graded according to World Health Organization criteria. Results The 5-FU test dose was well tolerated in all patients. Of 188 patients, 3 (1.6%) had marked alterations of 5-FU/5-FDHU pharmacokinetics (ie, 5-FU half-life [t½β] >5 hours, 5-FU total body clearance [CLTB] <1 L · h−1 · m−2, and 5-FDHU time to reach maximum plasma concentration [tmax] ≥45 minutes); they were excluded from 5-FU treatments and treated with irinotecan, which was well tolerated. The plasma disposition of 5-FU in the remaining 185 patients revealed an area under the curve (AUC) of 3.73 ± 2.18 h · μg/mL (mean ± SD), maximum plasma concentration (Cmax) of 16.78 ± 8.61 μg/mL, and t½β of 0.16 ± 0.15 hour, whereas the CLTB was 65.67 ± 31.86 L · h−1 · m−2. The 5-FDHU plasma profile showed a Cmax value of 3.64 ± 1.94 μg/mL, whereas the tmax value was 26.63 ± 10.06 minutes, with an AUC value of 3.71 ± 1.90 h · μg/mL. The PBMC DPD activity was 202.15 ± 141.14 pmol 5-FDHU · min−1 · mg−1 protein (95% confidence interval, 165–239.3 pmol 5-FDHU · min−1 · mg−1 protein). A significant correlation between 5-FU AUC and 5-FDHU AUC was found (r = 0.5492, P < .0001), whereas a weaker correlation between PBMC DPD activity and both 5-FDHU AUC (r = 0.328, P = .0121) and 5-FDHU Cmax (r = 0.369, P = .0044) was found. Interestingly, no relationships between PBMC DPD activity and common toxicities were found, whereas 5-FDHU tmax values greater than 30 minutes were associated with the risk of moderate to severe neutropenia and diarrhea (P = .0323 and P = .0138, respectively; chi-square test). Conclusions This study suggests a successful approach for preventing severe or life-threatening toxicities in gastrointestinal cancer patients who are candidates for standard 5-FU treatment by analyzing the 5-FU and 5-FDHU pharmacokinetic parameters after the administration of a reduced 5-FU test dose. Clinical Pharmacology & Therapeutics (2006) 80, 384–395; doi: 10.1016/j.clpt.2006.06.007" @default.
• W2032031944 created "2016-06-24" @default.
• W2032031944 creator A5003913815 @default.
• W2032031944 creator A5008203699 @default.
• W2032031944 creator A5025020524 @default.
• W2032031944 creator A5047673996 @default.
• W2032031944 creator A5056387623 @default.
• W2032031944 creator A5064230823 @default.
• W2032031944 creator A5077498316 @default.
• W2032031944 creator A5083540572 @default.
• W2032031944 creator A5083693387 @default.
• W2032031944 creator A5085351588 @default.
• W2032031944 date "2006-10-01" @default.
• W2032031944 modified "2023-09-27" @default.
• W2032031944 title "A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity" @default.
• W2032031944 cites W1552917964 @default.
• W2032031944 cites W1844681537 @default.
• W2032031944 cites W1860986539 @default.
• W2032031944 cites W1896741048 @default.
• W2032031944 cites W1963925513 @default.
• W2032031944 cites W1985716863 @default.
• W2032031944 cites W1986952772 @default.
• W2032031944 cites W2011646339 @default.
• W2032031944 cites W2011722350 @default.
• W2032031944 cites W2014749790 @default.
• W2032031944 cites W2029669006 @default.
• W2032031944 cites W2035486075 @default.
• W2032031944 cites W2065651620 @default.
• W2032031944 cites W2067463615 @default.
• W2032031944 cites W2068907962 @default.
• W2032031944 cites W2071412043 @default.
• W2032031944 cites W2089024911 @default.
• W2032031944 cites W2100021150 @default.
• W2032031944 cites W2100322741 @default.
• W2032031944 cites W2105008483 @default.
• W2032031944 cites W2117779481 @default.
• W2032031944 cites W2119027117 @default.
• W2032031944 cites W2125178818 @default.
• W2032031944 cites W2141878889 @default.
• W2032031944 cites W2145403343 @default.
• W2032031944 cites W2150730698 @default.
• W2032031944 cites W2155521795 @default.
• W2032031944 cites W2162072376 @default.
• W2032031944 cites W2235004388 @default.
• W2032031944 cites W2279815749 @default.
• W2032031944 cites W2396149304 @default.
• W2032031944 cites W2785266975 @default.
• W2032031944 doi "https://doi.org/10.1016/j.clpt.2006.06.007" @default.
• W2032031944 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17015056" @default.
• W2032031944 hasPublicationYear "2006" @default.
• W2032031944 type Work @default.
• W2032031944 sameAs 2032031944 @default.
• W2032031944 citedByCount "64" @default.
• W2032031944 countsByYear W20320319442012 @default.
• W2032031944 countsByYear W20320319442013 @default.
• W2032031944 countsByYear W20320319442014 @default.
• W2032031944 countsByYear W20320319442015 @default.
• W2032031944 countsByYear W20320319442016 @default.
• W2032031944 countsByYear W20320319442018 @default.
• W2032031944 countsByYear W20320319442019 @default.
• W2032031944 countsByYear W20320319442020 @default.
• W2032031944 countsByYear W20320319442021 @default.
• W2032031944 countsByYear W20320319442022 @default.
• W2032031944 countsByYear W20320319442023 @default.
• W2032031944 crossrefType "journal-article" @default.
• W2032031944 hasAuthorship W2032031944A5003913815 @default.
• W2032031944 hasAuthorship W2032031944A5008203699 @default.
• W2032031944 hasAuthorship W2032031944A5025020524 @default.
• W2032031944 hasAuthorship W2032031944A5047673996 @default.
• W2032031944 hasAuthorship W2032031944A5056387623 @default.
• W2032031944 hasAuthorship W2032031944A5064230823 @default.
• W2032031944 hasAuthorship W2032031944A5077498316 @default.
• W2032031944 hasAuthorship W2032031944A5083540572 @default.
• W2032031944 hasAuthorship W2032031944A5083693387 @default.
• W2032031944 hasAuthorship W2032031944A5085351588 @default.
• W2032031944 hasConcept C112705442 @default.
• W2032031944 hasConcept C123321153 @default.
• W2032031944 hasConcept C126322002 @default.
• W2032031944 hasConcept C2776694085 @default.
• W2032031944 hasConcept C2778050828 @default.
• W2032031944 hasConcept C2778397455 @default.
• W2032031944 hasConcept C2779804826 @default.
• W2032031944 hasConcept C2780456651 @default.
• W2032031944 hasConcept C29730261 @default.
• W2032031944 hasConcept C71924100 @default.
• W2032031944 hasConcept C90924648 @default.
• W2032031944 hasConcept C98274493 @default.
• W2032031944 hasConceptScore W2032031944C112705442 @default.
• W2032031944 hasConceptScore W2032031944C123321153 @default.
• W2032031944 hasConceptScore W2032031944C126322002 @default.
• W2032031944 hasConceptScore W2032031944C2776694085 @default.
• W2032031944 hasConceptScore W2032031944C2778050828 @default.
• W2032031944 hasConceptScore W2032031944C2778397455 @default.
• W2032031944 hasConceptScore W2032031944C2779804826 @default.
• W2032031944 hasConceptScore W2032031944C2780456651 @default.
• W2032031944 hasConceptScore W2032031944C29730261 @default.
• W2032031944 hasConceptScore W2032031944C71924100 @default.
• W2032031944 hasConceptScore W2032031944C90924648 @default.

• next